Temozolomide
- Generic Name
- Temozolomide
- Brand Names
- Temodar, Temomedac, Temodal, Temozolomide Sun, Temozolomide Accord, Temozolomide Teva
- Drug Type
- Small Molecule
- Chemical Formula
- C6H6N6O2
- CAS Number
- 85622-93-1
- Unique Ingredient Identifier
- YF1K15M17Y
- Background
Refractory anaplastic astrocytoma (WHO grade III) and Glioblastoma multiforme (WHO grade IV) are primary malignant brain tumours with poor prognosis and limited treatment options. Despite considerable genetic heterogeneity, these tumours often have impaired DNA repair systems, rendering them initially sensitive to alkylating agents, although they invariably ...
- Indication
Temozolomide is indicated in adult patients for the treatment of newly diagnosed glioblastoma concomitantly with radiotherapy and for use as maintenance treatment thereafter. It is also indicated for the treatment of refractory anaplastic astrocytoma in adult patients or adjuvant therapy for adults with newly diagnosed anaplastic astrocytoma.
- Associated Conditions
- Advanced Melanoma, High Grade Glioma: Glioblastoma (GBM), Primary Central Nervous System Lymphoma, Refractory Ewing Sarcoma, Refractory Neuroblastoma, Soft Tissue Sarcoma, Advanced Neuroendocrine tumor, Newly diagnosed Anaplastic Astrocytoma (AA), Refractory Anaplastic astrocytoma, Refractory, advanced Mycosis fungoides, Refractory, advanced Sezary Syndrome
- Associated Therapies
- -
Radiation Therapy With or Without Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
- Conditions
- First Posted Date
- 2003-12-24
- Last Posted Date
- 2012-09-24
- Target Recruit Count
- 575
- Registration Number
- NCT00006353
- Locations
- 🇨🇦
Centre Hospitalier de l'Universite de Montreal, Montreal, Quebec, Canada
🇨🇦Nova Scotia Cancer Centre, Halifax, Nova Scotia, Canada
🇨🇦Cross Cancer Institute, Edmonton, Alberta, Canada
Temozolomide, Thalidomide, and Lomustine in Treating Patients With Unresectable Stage III or Stage IV Melanoma
- Conditions
- First Posted Date
- 2003-11-06
- Last Posted Date
- 2013-01-18
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Registration Number
- NCT00072345
- Locations
- 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
Temozolomide and Thalidomide in Treating Patients With Brain Metastases Secondary to Melanoma
- Conditions
- Interventions
- First Posted Date
- 2003-11-06
- Last Posted Date
- 2013-01-17
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 50
- Registration Number
- NCT00072163
- Locations
- 🇺🇸
Cancer and Leukemia Group B, Chicago, Illinois, United States
Study of IV Edotecarin Vs Temozolomide or Carmustine (BCNU) or Lomustine (CCNU) in Patients With Glioblastoma Multiforme
- Conditions
- First Posted Date
- 2003-09-16
- Last Posted Date
- 2008-04-01
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 118
- Registration Number
- NCT00068952
- Locations
Pfizer Investigational Site
Temozolomide and Radiation Therapy in Treating Patients With Stage IV Malignant Melanoma With Measurable and Unresectable Cancer of the Central Nervous System
- Conditions
- Interventions
- First Posted Date
- 2003-09-11
- Last Posted Date
- 2016-12-15
- Lead Sponsor
- Alliance for Clinical Trials in Oncology
- Target Recruit Count
- 41
- Registration Number
- NCT00068666
- Locations
- 🇺🇸
John Stoddard Cancer Center at Iowa Methodist Medical Center, Des Moines, Iowa, United States
🇺🇸Mayo Clinic Scottsdale, Scottsdale, Arizona, United States
🇺🇸Mercy Capitol Hospital, Des Moines, Iowa, United States
Temozolomide in Treating Adults With Newly Diagnosed Primary Malignant Glioblastoma Multiforme
- Conditions
- First Posted Date
- 2003-08-20
- Last Posted Date
- 2013-06-20
- Lead Sponsor
- Duke University
- Target Recruit Count
- 50
- Registration Number
- NCT00003464
- Locations
- 🇺🇸
Duke Comprehensive Cancer Center, Durham, North Carolina, United States
Temozolomide Plus PEG-Interferon Alfa-2B in Treating Patients With Advanced Solid Tumors
- Conditions
- First Posted Date
- 2003-07-30
- Last Posted Date
- 2018-03-30
- Lead Sponsor
- Dartmouth-Hitchcock Medical Center
- Registration Number
- NCT00014261
- Locations
- 🇺🇸
Norris Cotton Cancer Center, Lebanon, New Hampshire, United States
Temozolomide in Treating Patients With Recurrent or Progressive Malignant Glioma
- Conditions
- First Posted Date
- 2003-07-18
- Last Posted Date
- 2014-01-06
- Lead Sponsor
- Herbert Irving Comprehensive Cancer Center
- Registration Number
- NCT00004204
- Locations
- 🇺🇸
Cleveland Clinic Taussig Cancer Center, Cleveland, Ohio, United States
🇺🇸Nalitt Institute for Cancer And Blood Related Diseases, Staten Island, New York, United States
🇺🇸Stanford University Medical Center, Stanford, California, United States
Irinotecan Followed by Radiation Therapy and Temozolomide in Treating Children With Newly Diagnosed Brain Tumor
- Conditions
- First Posted Date
- 2003-05-08
- Last Posted Date
- 2011-10-04
- Lead Sponsor
- St. Jude Children's Research Hospital
- Target Recruit Count
- 53
- Registration Number
- NCT00004068
- Locations
- 🇺🇸
Saint Jude Children's Research Hospital, Memphis, Tennessee, United States
Temozolomide in Treating Patients With Relapsed or Progressive Small Cell Lung Cancer
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-07-11
- Lead Sponsor
- Fox Chase Cancer Center
- Target Recruit Count
- 7
- Registration Number
- NCT00022711
- Locations
- 🇺🇸
Kimball Medical Center, Lakewood, New Jersey, United States
🇺🇸Fox Chase Cancer Center at Virtua Memorial Hospital Burlington County, Mount Holly, New Jersey, United States
🇺🇸South Jersey Regional Cancer Center, Millville, New Jersey, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.